Keyword: Herceptin

Roche could use a speedy Kadcyla label expansion to help quiet concerns about mounting biosimilar competition to its aging blockbusters.

Roche expects 2019 sales growth in low- to mid-single digits, compared with 7% in 2018, partially on expected U.S. biosimilar launches.

The European exodus from branded Humira to biosimilars confirms that AbbVie was was way too optimistic about sales erosion, a Bernstein report reveals.

With biosim rivals looming, Roche will need its newer meds to step up, and Wednesday's Kadcyla data could give its breast cancer franchise a boost.

Genentech filed a lawsuit against former employees accused of stealing trade secrets, calling on a court to issue an injunction and award damages.

The Herceptin sales decline is a preview of how biosimilar competition could impact the top lines of Roche and other innovators, Bernstein says.

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

Roche is teeing up a new use for its breast cancer drug Kadcyla, hoping to gin up sales as Herceptin biosimilars hurtle toward the U.S. market.

An independent panel of FDA advisers endorsed Celltrion’s Rituxan biosimilar, sending the program to the FDA for a final say.